Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 8/20 | 0.77 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331510 | 0.97 | CCR3 (0.81) | CCR3EPHX2EPHX1SLC6A2SLC6A3 | |
| SCHEMBL6407882 | 0.85 | CCR3 (0.65) | CCR3EPHX2EPHX1MAPK1 | |
| SCHEMBL6330827 | 0.81 | CCR3 (0.93) | CCR3TMEM97SLC6A2SLC6A3 | |
| SCHEMBL6338952 | 0.79 | EPHX2 (0.55) | CCR3EPHX2EPHX1SLC6A2SLC6A3 | |
| SCHEMBL7499307 | 0.79 | EPHX2 (0.55) | CCR3EPHX2EPHX1SLC6A2SLC6A3 | |
| SCHEMBL12931905 | 0.78 | EPHX2 (0.90) | EPHX2EPHX1MAPK1 | |
| SCHEMBL6333410 | 0.78 | EPHX2 (0.62) | CCR3EPHX2EPHX1MAPK1 | |
| SCHEMBL4199400 | 0.78 | EPHX2 (1.00) | EPHX2EPHX1MAPK1 | |
| SCHEMBL12196187 | 0.78 | EPHX2 (1.00) | EPHX2EPHX1MAPK1 | |
| SCHEMBL14559598 | 0.77 | CCR3 (0.75) | CCR3TMEM97SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-25 | — | — | US | claimed |
| US-6906066-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-25 | — | — | US | disclosed |
| US-6605623-B1 | Prevention of asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA CO. | 2003-08-12 | — | — | US | disclosed |
| EP-1140086-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1140086-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035451-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058960-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885EPHX2 1687/4885EPHX1 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.